Lutsentis - innovation in medicine

Curing age-related macular degeneration of the retina is now possible thanks to Lucentis!

Therapy of macular degeneration of the retina "The most common factor of vision loss, visual acuity in people of the older generation is the appearance of retinal degeneration," states the World Health Organization.

This is a degenerative disorder of a permanent nature, which appears in people after 55 years of age, most often in females. Medical practice divides the disease into two types: "wet" and "dry" degeneration.

"Dry" degeneration of the retina progressively develops over many years and leads to a profound loss of central vision in 15-20% of those suffering from macular degeneration.

With a "wet" form, everything is much worse: it develops in a few weeks or months and occurs in 3-4 patients out of 10.

The drug Lucentis - widely used in practice by the Moscow Eye Clinic - mgkl.ru.

The reasons for the development of the visual impairment may be: age - after 55 years, most often in women - people who suffer from cardiovascular disorders or hypertension - a long habit of smoking

The nature of the disease - progressive and rapid development and changes in the retina - usually an absolute loss of vision throughout the year. - the clonic intervention occurs about 14 months from the time of the detection of symptoms.

Manifestations and complaints at the initial stage of macular degeneration of the retina: - Sharp loss of visual acuity - Central scotoma - Development of metamorphosis - Objects seem fuzzy - Sensitivity to contrast sharply decreases

Treatment of degeneration of the retina occurs in order to prevent the growth of a blood vessel of abnormal origin through the blocking of stimulants of the appearance of new abnormal vessels and the destruction of the effect on an already identified neovascular network in order to stop or prevent bleeding.

Until now, no method has been worthy of treatment, and the disease has been treated as a series of incurable diseases. But the appearance on the market of medicine Lucentis, the situation gained positive momentum. In the summer of 2006, it was approved as the only means to combat macular degeneration of the retina. The drug is able to slow the progressive development of the disease, and in some cases (if the treatment situation is not started) to improve the acuity of the vision. Medical institutes have developed Lucentis for use in ophthalmology. This fact gives him safety and efficiency. Due to the preparation, the excess stimulation of angiogenesis decreases, the net thickness is normal, pathogenetic method is provided in treatment due to the effect on the growth of new vessels of active isoforms.